ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Sponsor: Noveome Biotherapeutics, formerly Stemnion
Listed as NCT03687632, this PHASE2 trial focuses on Persistent Corneal Epithelial Defect and remains completed. Sponsored by Noveome Biotherapeutics, formerly Stemnion, it has been updated 16 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Noveome Biotherapeutics, formerly Stemnion
For direct contact, visit the study record on ClinicalTrials.gov .